Last reviewed · How we verify
Intra articular injection with Ropivacaine
At a glance
| Generic name | Intra articular injection with Ropivacaine |
|---|---|
| Also known as | Naropin |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- Suprascapular Nerve Block to Improve Tolerance and Outcomes of Shoulder Hydrodistension in Adhesive Capsulitis (NA)
- Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy (NA)
- Frozen Shoulder and Hormone Replacement Therapy (PHASE4)
- Trial for Treating Painful Degenerative Disc Disease (NA)
- Frozen Shoulder Treatment with Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block (NA)
- "Comparison of Intra-articular of 0.2% Ropivacaine vs. 0.75% Ropivacaine in Postoperative of Knee Arthroscopy" (PHASE4)
- Comparison Ultrasound-Guided Adductor Canal Block and Surgeon-Performed Block for Pain Management After Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra articular injection with Ropivacaine CI brief — competitive landscape report
- Intra articular injection with Ropivacaine updates RSS · CI watch RSS
- Mayo Clinic portfolio CI